药明康德成交额达100亿元，现涨2.26%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 ...

截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | -- ...

主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金80.79亿元， 其次是计算机行业，净流出资金为70.10亿元，净流出资金较多的还有电力设备、汽车、国防军工等行 业。 医药生物行业今日上涨2.79%，全天主力资金净流入34.75亿元，该行业所属的个股共474只，今日上涨 的有373只，涨停的有14只；下跌的有98只，跌停的有1只。以资金流向数据进行统计，该行业资金净流 入的个股有216只，其中，净流入资金超亿元的有16只，净流入资金居首的是药明康德，今日净流入资 金10.40亿元，紧随其后的是长春高新、恒瑞医药，净流入资金分别为5.99亿元、5.24亿元。医药生物行 业资金净流出个股中，资金净流出超亿元的有7只，净流出资金居前的有博瑞医药、爱尔眼科、美年健 康，净流出资金分别为2.11亿元、1.86亿元、1.82亿元。（数据宝） 医药生物行业资金流入榜 沪指9月1日上涨0.46%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为通信、综合，涨幅分 别为5.22%、4.27%。医药生物行业今日上涨2.79%。跌幅居前的行业为非银金融、银行，跌幅分别为 1.28%、1.03%。 ...

沪指9月1日上涨0.46%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为通信、综合，涨幅分别为5.22%、4.27%。医药生物行业今日上涨2.79%。跌幅居前的行业为非银金融、银行 资金面上看，两市主力资金全天净流出513.00亿元，今日有8个行业主力资金净流入，医药生物行业主力资金净流入规模居首，该行业今日上涨2.79%，全天净流入资金34.75亿元，其次是通信 主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金80.79亿元，其次是计算机行业，净流出资金为70.10亿元，净流出资金较多的还有电力设备、汽车、国 医药生物行业今日上涨2.79%，全天主力资金净流入34.75亿元，该行业所属的个股共474只，今日上涨的有373只，涨停的有14只；下跌的有98只，跌停的有1只。以资金流向数据进行统计， 医药生物行业资金流入榜 医药生物行业资金流出榜 ...

Core Insights - WuXi AppTec's stock increased by 5.19% to 108.66 CNY per share, with a trading volume of 6.298 billion CNY and a turnover rate of 2.39%, resulting in a total market capitalization of 320.711 billion CNY [1] Company Overview - WuXi AppTec, established on December 1, 2000, and listed on May 8, 2018, is located in Shanghai and Hong Kong. The company provides comprehensive integrated platform services for the discovery, development, and production of small molecule chemical drugs [1] - The revenue composition of WuXi AppTec includes: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Terminated operations 1.90%, Other businesses 0.79% [1] Fund Holdings - According to data, one fund under Guolian An Fund holds a significant position in WuXi AppTec. The Guolian An CSI Pharmaceutical 100A fund (000059) reduced its holdings by 2,800 shares in the second quarter, now holding 35,500 shares, which accounts for 1.04% of the fund's net value, ranking it as the fourth-largest holding [2] - The Guolian An CSI Pharmaceutical 100A fund was established on August 21, 2013, with a latest scale of 178 million CNY. Year-to-date returns are 19.34%, ranking 2403 out of 4222 in its category, while the one-year return is 34.98%, ranking 2704 out of 3779 [2]

Group 1 - Foreign investment giants are increasing their holdings in Chinese assets, with institutions like JPMorgan, Citigroup, and Morgan Stanley boosting their positions in H-shares such as CATL, ZTE, and WuXi AppTec [1] - JPMorgan raised its stake in CATL H-shares from 5.98% to 6.06%, while Citigroup increased its holdings in ZTE H-shares to 7.17%, and Morgan Stanley significantly raised its stake in Ganfeng Lithium H-shares from 4.20% to 6.06% [1] - Global hedge funds are expected to see their buying scale of Chinese stocks in August reach a monthly high since February [1] Group 2 - The Hong Kong stock market continued its upward trend, with the Hang Seng Index rising by 0.32% and the Hang Seng Tech Index increasing by 0.54% on August 29 [2] - In August, the Hang Seng Index accumulated a rise of 1.23%, marking four consecutive months of gains, while the Hang Seng Tech Index and the National Enterprises Index rose by 4.06% and 0.73%, respectively [2] - Southbound funds recorded a net purchase of HKD 120.46 billion on August 29, with a total net purchase of HKD 112.1 billion for the month, indicating strong enthusiasm for mainland capital allocation [2] Group 3 - Institutions are generally optimistic about the upward potential of the Hong Kong stock market, with Citic Securities expecting a boost from increased domestic growth policies and improvements in global liquidity [2] - China International Capital Corporation noted that despite short-term liquidity impacts, the long-term structural advantages of the Hong Kong stock market remain significant [2] - Analysts from Huatai Securities emphasized that expectations of U.S. Federal Reserve rate cuts, demand for southbound allocations, and high-quality companies listing in Hong Kong are core support factors for the market [2]

Group 1 - The core point of the article highlights that WuXi AppTec's trading volume reached 10 billion yuan, with a current increase of 8.15% [1]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Group 1 - The stock price of WuXi AppTec has increased by over 5% during trading, currently reported at 100.78 yuan [1]